Orphagen Pharma Receives NIH Grant to Advance IBD Drug
09 Dec 2024 //
BUSINESSWIRE
Orphagen Pharma Receives Rare Pediatric Disease Designation from FDA for OR-449
17 Jan 2023 //
BUSINESSWIRE
Orphagen Pharma Presents Data on Downstream Targets of SF-1 Antagonist OR-449
11 Jun 2022 //
BUSINESSWIRE